Citi downgraded Hims & Hers to Sell from Neutral with a $25 price target Stay Ahead of the Market:Discover outperforming stocks and invest ...
What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...
Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the ...
Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...
Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations.
Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its ...
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.
Ratings for Hims & Hers Health HIMS were provided by 12 analysts in the past three months, showcasing a mix of bullish and ...
Hims & Hers Health (NYSE:HIMS – Free Report) had its target price lifted by Piper Sandler from $21.00 to $24.00 in a report ...
Bearish flow noted in Hims and Hers Health with 25,948 puts trading, or 1.4x expected. Most active are Mar-25 27 puts and Jan-25 26 puts, with ...